Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has announced the unblinded results of a phase one clinical trial that supports further development of its drug AMP945 in cancer and fibrosis.

To view media story please click here.